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Abstract We assessed the clinical features and treatment of
pediatric patients with drug-induced anaphylaxis in clinical
settings. Pediatric drug-induced anaphylaxis cases collected
by the Beijing Pharmacovigilance Database from 2004 to
2014 were analyzed. A total of 91 cases were identified.
Drug-induced anaphylaxis was primarily caused by antibi-
otics (53%). Children of 0–5 years were more likely to
develop cyanosis symptoms than children of 13–17 years
(OR = 5.14, 95%CI [1.74, 15.20], P = 0.002). Children of
13–17 years were more likely to develop hypotension than
children of 6–12 years (OR = 11.79, 95%CI [2.28, 60.87],
P = 0.002), and to manifest both neurological symptoms
(OR = 3.56, 95%CI [1.26, 10.08], P = 0.015) and severe ana-
phylaxis than children of 0–5 years (OR = 15.46, 95%CI
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[1.85, 129.33], P = 0.002). Supratherapeutic doses of epineph-
rine were more likely with intravenous (IV) bolus (92%) in
contrast to either intramuscular (IM) (36%, OR = 19.25,
95%CI [1.77, 209.55], P = 0.009) or subcutaneous (SC) injec-
tions (36%, OR = 19.80, 95% CI [1.94, 201.63], P = 0.005).
Only 62 (68%) patients received epinephrine treatment as the
first-line therapy.
Conclusion: This study demonstrates that antibiotics were
the most common cause of pediatric drug-induced anaphylax-
is. Children may present with different anaphylactic signs/
symptoms based on age groups. Epinephrine is under-
utilized and provider education on the proper management
of drug-induced anaphylaxis is warranted.
What is Known:
• The most common causes of anaphylaxis in children are allergies to
foods. Drugs are the second most common cause of pediatric
anaphylaxis.
• IM epinephrine is the recommended initial treatment of anaphylaxis.
What is New:
•Drug-induced anaphylaxis in pediatric patients has age-related clinical
features.
• IV bolus epinephrine was overused and associated with
supratherapeutic dosing.
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Abbreviations
DIA Drug-induced anaphylaxis
ED Emergency department
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BPD Beijing Pharmacovigilance Database
OR Odds ratio
CI Confidence intervals
TCM Traditional Chinese medicine
Introduction
Anaphylaxis, the most severe manifestation of an acute allergic
reaction, is a medical emergency and in rare cases may cause
death [25]. It typically involves two or more body systems in-
cluding skin and/or mucosa, upper and lower respiratory tract,
gastrointestinal tract, cardiovascular system, and central nervous
system [25]. First-line treatment for anaphylaxis is intramuscular
(IM) epinephrine injection in the anterolateral thigh [25].
Pediatric emergency department (ED) visits for children with
anaphylaxis increased from 5.7 to 11.7 per 10,000 visits from
2009 to 2013 in the USA [14, 20], and this has become an
important health issue. The most common causes of anaphylaxis
in children are allergies to foods, followed by medications, sting-
ing insect venom, blood products, immunotherapy, latex, vac-
cines, and contrast media [13, 33].
Despite drug-induced anaphylaxis (DIA) being the second
most common cause of pediatric anaphylaxis [12], informa-
tion on its characteristics and management is limited, and data
on DIA in children outside the USA and Europe is sparse.
Here, we present an analysis of 91 pediatric DIA cases based
on data extracted from the Beijing Pharmacovigilance
Database (BPD) from 2004 to 2014. The purpose of the study
was to evaluate the elicitors, describe the main clinical mani-
festations of anaphylaxis and treatment of DIA in pediatric
patients.
Materials and methods
Study participants
This study was considered to be exempt from further review
by the Institutional Review Board, Peking University Third
Hospital. We utilized the BPD provided by the Beijing
Center for Adverse Drug Reaction Monitoring (BCADR)
for this study. A total of 94 participating hospitals in the
Beijing region are required to report severe adverse drug
event (ADE) cases to this database. Cases are self-reported
to the respective pharmacy department by physicians,
nurses, and pharmacists. The BPD is created to collect
well-defined and standardized data of affected patients
experiencing ADEs in the Beijing region of China. We
identified all patients with a reported drug-induced acute
allergic reaction or anaphylaxis using the following search
terms: Banaphylaxis,^ Banaphylactic shock,^ Ballergy,^
Ballergic reaction,^ and Bhypersensitivity^ from the BPD
database for the period covering January 1, 2004 to
December 31, 2014. A data extraction form was developed
to validate the diagnosis and severity of anaphylaxis and the
use of epinephrine. The form was tested and revised based
on a pilot analysis of database records from 250 patients.
Two trained extractors performed the extraction indepen-
dently to ensure consistency, and discrepancies were re-
solved by an experienced investigator with expertise in
standardized medical record extraction. Two physician ad-
judicators independently determined the diagnosis of ana-
phylaxis and assessed the case severity based on the infor-
mation extracted from each case. All disagreements were
resolved through discussions. We divided the severity of
each anaphylaxis case into either mild to moderate or severe
categories (Appendix 1) [3]. The information on BCADR,
detailed case query strategy and data extraction from our
research team has been previously published [32, 34], in
which a cohort of 1189 DIA patients were identified. A
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subgroup of pediatric patients (less than 18 years of age)
from the base cohort was included in this analysis.
Study design
Patient’s age was categorized into three strata: 0–5, 6–12, and
13–17 years.We investigated differences between groupswith
regards to admission diagnosis, suspected elicitors, organ sys-
tems’ involvement, and therapies to treat anaphylaxis. We
analyzed the dose and the administration route (intravenous
IV, IM, and subcutaneous SC) of epinephrine. To analyze the
supratherapeutic dosing of epinephrine, initial pediatric epi-
nephrine dosing was categorized into non-supratherapeutic or
supratherapeutic [11, 17] as determined by weight-based dos-
ing (≤ 0.01 mg/kg vs > 0.01 mg/kg of 1:1000 solution with a
maximum dose of 0.5 mg for IM and SC routes, and or
0.001 mg/kg for IV bolus with a maximum dose of 0.1 mg
of 1:10,000 solution). When weights were not available, we
assessed the pediatric IM/SC epinephrine dosing based on age
groups (<6, 6–12, and >12 years) [28], and for IV bolus we
used age to estimate body weight [31] to calculate the dose.
We did not analyze supratherapeutic dosing with epinephrine
IV continuous infusion as it is usually titrated to clinical ef-
fects, and not all the necessary information for calculating the
total dose was available, such as the exact time for dose
modifications.
We compared the baseline information, anaphylactic symp-
toms, outcome for patients receiving epinephrine monothera-
py, corticosteroid monotherapy, as well as epinephrine and
corticosteroid combination therapy. We also compared out-
comes between patients who received epinephrine as an initial
treatment and patients who did not receive it as an initial
treatment.
Statistical analyses
The statistical analysis was performed using the SPSS version
18 (SPSS Inc., IL, USA). Dosing data across age groups were
expressed as median (min, max) and compared using the
Kruskal-Wallis test, depending on non-normality. If the P val-
ue of the Kruskal-Wallis test is less than 0.05, the Wilcoxon
rank sum test was conducted for pairwise comparisons be-
tween groups. The dichotomous variables were described as
frequency (percentage) and differences from age groups were
compared using the Pearson’s chi-square test (when no cell in
the table have an expected count less than 1, and no more than
20% of the cells should have an expected count less than 5) or
the Fisher’s exact test. The P values of pairwise comparisons
were adjusted by the Bonferroni correction for multiple com-
parisons. All tests were two-tailed tests, where a difference
with P < 0.05 was considered to be statistically significant.
Data availability The data that support the findings of this
study are available from the BCADR, but restrictions apply to
the availability of these data, which were used under license
for the current study, and so are not publicly available. Data
are, however, available from the authors upon reasonable re-
quest and with permission from the BCADR.
Results
Patients and anaphylaxis elicitors
A total of 9425 patients with drug-induced hypersensi-
tivity reactions were identified from the BPD using our
search terms, and 91 pediatric patients were ultimately
included in our analysis (flowchart is shown in
Appendix 2). The majority of patients (88, 97%) devel-
oped anaphylaxis during their hospitalizations, and 3 pa-
tients presented to an ED. Of the 88 inpatients, the num-
ber of patients who received anaphylaxis treatment in
EDs and non-ED settings were 11(13%) and 77(88%),
respectively. Of the 91 patients, 35% were 0–5 year
old, 26% were 6–12 year old, and 39% were 13–17 year
old; and 62% of the patients were males (Table 1). There
were no significant differences for admission diagnoses
and elicitors among the three age groups, except for a
significant difference between the 6–12 years group and
13–17 years group for biologics use (P = 0.032).
Clinical features
The majority of patients with anaphylaxis experienced cardio-
vascular and respiratory symptoms, and approximately half of
the patients developed mucocutaneous manifestations
(Table 2). Notably, the 0–5 years group was more likely to
develop cyanosis than the 13–17 years group (OR = 5.14,
95%CI [1.74, 15.20], P = 0.002), whereas the 13–17 years
group were more likely to develop hypotension than the 6–
12 years group (OR = 11.79, 95%CI [2.28, 60.87], P = 0.002)
and neurological symptoms than the 0–5 years group (OR =
3.56, 95%CI [1.26, 10.08], P = 0.015). The 13–17 years group
was also more likely to develop severe anaphylaxis (OR =
15.46, 95%CI [1.85, 129.33], P = 0.002).
Analysis of therapies for the treatment of anaphylaxis
A total of 62 patients (68%) received epinephrine for anaphy-
laxis, but only 49 (54%) received it as an initial treatment.
Forty-eight patients had an adequate documentation of admin-
istration routes; the number of patients who received IM, SC,
IV bolus injection, and IV continuous infusion were 11 (23%),
16 (33%), 15 (31%), and 6 (13%), respectively. Thirty-seven
patients had a clear documentation for both the administration
Eur J Pediatr (2018) 177:145–154 147
route and dosing of epinephrine. A total of 73 (80%) patients
received corticosteroids and 68 (75%) received corticosteroid
as initial therapy including 34 (37%) on corticosteroid alone
and the other 34 (37%) on both corticosteroid and epineph-
rine. A total 29 (32%) patients received antihistamines, and
only 4 (4%) patients received bronchodilators. There was no
significant difference among the three different age groups
with regards to the route of administration for epinephrine,
the route of administration for corticosteroids, or the initial
drug therapy of anaphylaxis (Appendix 3).
Table 1 Demographics, original
diseases, and elicitors of DIA in
children by age group
All no.
(%)
(n = 91)
0–5 years
no. (%)
(n = 32)
6–12 years
no. (%)
(n = 24)
13–17 years
no. (%)
(n = 35)
χ2 P *
Demographics
Male 56(62) 20(63) 11(46) 25(71) 3.960 0.138
Female 35(39) 12(38) 13(54) 10(29)
Admission diagnoses
Infectious 49(54) 20(63) 12(50) 17(49) 1.499 0.473
RTI 38(42) 18(56) 8(33) 12(34) 4.267 0.118
Stress/operation/trauma 15(17) 3(9) 2(8) 10(29) 0.061
Tumor 10(11) 4(13) 3(13) 3(9) 0.837
Gastrointestinal disease 8(9) 3(9) 2(8) 3(9) 1.000
Rheumatological
disease
4(4) 2(6) 2(8) 0(0) 0.184
Asthma 1(1) 0(0) 1(4) 0(0) 0.264
Cardiovascular disease 2(2) 0(0) 0(0) 2(6) 0.334
Other diseases† 0(0) 0(0) 0(0) 0(0) –
Elicitors
Antibiotics 48(53) 17(53) 14(58) 17(49) 0.547 0.761
Cephalosporins 31(34) 13(41) 10(42) 8(23) 3.188 0.203
Macrolides 7(8) 1(3) 3(13) 3(9) 0.421
Penicillins 3(3) 0(0) 1(4) 2(6) 0.479
Other antibiotics‡ 7(8) 3(9) 0(0) 4(11) 0.282
TCM injection¶ 8(9) 2(6) 1(4) 5(14) 0.453
Biologics 7(8) 1(3) 0(0) 6(17) 0.032
Radiocontrast agents 4(4) 0(0) 3(13) 1(3) 0.088
Glucocorticoids 3(3) 0(0) 1(4) 2(6) 0.479
Chemotherapeutic
agents
3(3) 1(3) 1(4) 1(3) 1.000
Anesthetics 3(3) 3(9) 0(0) 0(0) 0.057
IV mucosolvan 2(2) 2(7) 0(0) 0(0) 0.189
Antivirus 1(1) 1(3) 0(0) 0(0) 0.615
Vaccine 0(0) 0(0) 0(0) 0(0) – –
NSAIDs 0(0) 0(0) 0(0) 0(0) – –
Others§ 11(12) 4(13) 4(17) 3(9) 0.606
RTI, respiratory tract infection; TCM, Traditional Chinese medicine; IV, intravenous; NSAIDs, non-steroid anti-
inflammatory drugs
*P values are from Fisher’s exact test or Pearson’s chi-square test of difference across age groups
†Other diseases including 1 patient with epilepsy, 1 patient with cerebral palsy, and 1 patient with short stature
‡Other antibiotics include 3 patients on levofloxacin, 2 patients on vancomycin, 1 patient on lincomycin, and 1
patient on metronidazole
¶The 8 TCM injections are Qingkailing, Shuanghuanglian, Houttuynia, Xiyanping, Xingnaojing, Ligustrazine,
and Dehydroandrograpolide (for 2 cases)
§Other medications include calcium dibutyryladenosine cyclophosphate for injection, etamsylate injection,
hydroxyethyl starch 200/0.5200/0.5), succinylated gelatin injection, a coenzyme A for injection, levobunolol
hydrochloride ophthalmic solution, vitamin K1 injection, colloidal aluminum phosphate gel, fat-soluble vita-
min(1) for injection
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Analysis of initial administration routes and initial dosing
of epinephrine
A total of 49 patients received epinephrine as initial therapy,
including 15 (17%) on epinephrine alone and 34 (37%) on
both epinephrine and corticosteroid. Among the 49 patients,
data were available from 37 patients with clearly documented
initial administration routes of epinephrine and severities of
anaphylaxis. The percentage with IM injection, SC injection,
IV bolus and IV continuous infusion route was 26, 40, 26, and
9%, respectively. There was no significant difference for num-
ber of patients by each administration route (P = 0.074).
Table 2 Clinical manifestations
during anaphylaxis reactions of
children by age group
All no. (%)
(n = 91)
0–5 years no.
(%) (n = 32)
6–12 years no.
(%) (n = 24)
13–17 years no.
(%) (n = 35)
χ2 P *
Mucocutaneous 54(59) 22(69) 14(58) 18(51) 2.092 0.351
Flushing 21(23) 11(34) 4(17) 6(17) 3.551 0.169
Pruritus 16(18) 4(13) 5(21) 7(20) 0.649
Diffuse
urticaria
33(36) 13(41) 8(33) 12(34) 0.412 0.814
Angioedema 10(11) 4(13) 3(13) 3(9) 0.837
Conjunctivitis 9(10) 2(6) 3(13) 4(11) 0.742
Respiratory
system
66(73) 25(78) 19(79) 22(63) 2.677 0.265
Rhinorrhea 1(1) 0(0) 1(4) 0(0) 0.264
Cough 3(3) 0(0) 0(0) 3(9) 0.111
Voice change 3(3) 0(0) 1(4) 2(6) 0.479
Dyspnea 22(24) 7(22) 7(29) 8(23) 0.517 0.822
Wheezing 21(23) 7(22) 7(29) 7(20) 0.772 0.704
Cyanosis 36(40) 18(56) 11(46) 7(20) 9.724 0.008
Respiratory
arrest
2(2) 1(3) 0(0) 1(3) 1.000
Hypoxemia 8(9) 2(6) 4(17) 2(6) 0.368
Cardiovascular
system
71(78) 23(72) 15(63) 33(94) 9.476 0.009
Hypotension 69(76) 22(69) 14(58) 33(94) 11.386 0.003
Cardiac arrest 1(1) 0(0) 0(0) 1(3) 1.000
Incontinence 3(3) 0(0) 1(4) 2(6) 0.479
Gastrointestinal
system
33(36) 10(31) 10(42) 13(37) 0.663 0.718
Emesis 27(30) 8(25) 9(38) 10(29) 1.060 0.589
Nausea 12(13) 0(0) 5(21) 7(20) 0.010
Abdominal
cramping
13(14) 5(16) 5(21) 3(9) 0.382
Diarrhea 0(0) 0(0) 0(0) 0(0) – –
Neurological
system
35(39) 8(25) 8(33) 19(54) 6.420 0.040
Presyncope 22(24) 6(19) 6(25) 10(29) 0.892 0.640
Syncope 17(19) 6(19) 2(8) 9(26) 0.254
Convulsion 4(4) 1(3) 0(0) 3(9) 0.447
Severity of anaphylaxis
Mild to
moderate
15(17) 10(31) 4(17) 1(3) 0.005
Severe 76(84) 22(69) 20(83) 34(97)
Outcome
Death 1(1) 0(0) 0(0) 1(3) 1.000
ICU
admission
7(8) 4(13) 2(8) 1(3) 0.325
ICU, intensive care unit
*P values are from Fisher’s exact test or Pearson’s chi-square test of difference across age groups
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Overall, there was no significant difference in terms of ana-
phylaxis severity between each administration route (P =
0.940). There was a significant difference regarding the fre-
quency of supratherapeutic dosing of epinephrine by each
administration route (χ2 = 10.407, P = 0.005) (Table 3). A
supratherapeutic dosing was more likely with the IV bolus
route (11/12) compared to IM (5/14, OR = 19.25, 95%CI
[1.77, 209.55], P = 0.009), and SC (4/11, OR = 19.80,
95%CI [1.94, 201.63], P = 0.005). The anaphylaxis severity
was not associated with supratherapeutic dosing by an admin-
istration route (χ2 = 1.481, P = 0.512) (Table 3). There was no
difference by age in the anaphylaxis treatment and adminis-
tration for epinephrine.
A total of 20 (54%) patients received supratherapeutic dosing
of epinephrine (Table 4). Thirteen patients were overdosed accord-
ing to the maximum dose of the corresponding administration
routes, dosing for 11 patients with IV bolus route exceeded the
maximum dose of 0.1mg, and dosing for 2 patients with IM route
exceeded the maximum dose of 0.5 mg. Seven patients under
6 years old were overdosed according to maximum dose of
0.15 mg for this age group (Table 4).
Among 91 cases, only 1 patient died and this patient was treat-
ed initially with epinephrine; 7 patients were admitted to ICU, of
those 4 patients received epinephrine (2 were initially treated) and
2 were treated with supratherapeutic doses. There was no signifi-
cant difference regarding outcome between patients who received
epinephrine as an initial treatment and those who did not (χ2 =
4.437,P= 0.229, Appendix 4). Overall, our analysis showed there
were no significant association between symptoms and use of
epinephrine, whether use epinephrine as an initial treatment, or
administration route of epinephrine (Appendix 5–7).
Discussion
Using the BPD data, our study is the first to analyze the clin-
ical features and treatment of pediatric DIA patients in clinical
settings over a decade in Beijing, China. A total of 91 pediatric
cases were identified and assessed, accounting for 7.7% (91/
1189) of both adult and pediatric DIA patients. Antibiotics,
TCM injections and biologics were the top three drug triggers.
The most common anaphylactic clinical features were mani-
festations of the cardiovascular and respiratory systems, and
children may present signs and symptoms differently based on
age groups. Epinephrine is underutilized, and only 54% re-
ceive it as the initial treatment. Only 23% of patients received
epinephrine by the IM route, suggesting the administration
route is not appropriate. The percentage of supratherapeutic
dose of epinephrine is high, 92% (11/12) for the IV bolus, and
36% (5/14) for IM, and 36% (4/11) for SC. Furthermore, the
overdose frequency of IV bolus was significantly higher than
both IM and SC combined.
Demographics and elicitors of pediatric patients with DIA
The higher frequency for males in the 0–5 year and the 13–
17 year age groups is consistent with the data from the
European anaphylaxis registry [10] reporting that boys are
more likely to experience anaphylaxis. Infectious diseases,
stress/operation/trauma and tumor were the principal admis-
sion diagnoses; disease distribution was similar among the
three age groups. Although asthma is considered to be one
of the important risk factors for anaphylaxis [9, 15], there
was only one case with a current asthma diagnosis in our
study, possibly related to our small sample size or the relative-
ly low prevalence of asthma in China [22].
Antibioticswere themost common trigger,which is in linewith
a few previous studies indicating antibiotics are the most common
cause of DIA [9, 19, 23]. Our study suggests that clinical signs and
symptoms related to anaphylaxis should be closely monitored
when children are administered antibiotics in the hospital setting,
particularly β-lactams. Unlike the US or the European reports,
TCM injections were the next most common cause of DIA, in-
cludingQingkailing, Shuanghuanglian,Houttuynia, etc., which is
Table 3 Dosing and route of epinephrine administration associated with severity of anaphylaxis
Severity of
anaphylaxis
IM injection, no. (%) (n = 11) SC injection, no. (%) (n = 14) IV bolus, no. (%) (n = 12)
Supratherapeutic
dosing
Recommended
dosing
P Supratherapeutic
dosing
Recommended
dosing
P Supratherapeutic
dosing
Recommended
dosing
P
Mild to
moderate
1(25) 2(29) 1.000 2(40) 1(11) 0.505 0(0) 1(100) 0.083
Severe 3(75) 5(71) 3(60) 8(89) 11(100) 0(0)
P values are from Fisher’s exact test of difference across age groups. Data were available from 37 patients with clearly documented administration routes
(IM injection, SC injection, and IV bolus) and dose of epinephrine. Overall, there is no significant difference regarding the severity of anaphylaxis in each
administration route (P = 0.512). There was no significant difference between the percentage of severe anaphylaxis between recommended and
supratherapeutic dosing groups in each administration route group (P value is 1.000, 0.505, and 0.083 for IM, SC, and IV bolus, respectively).
Overall, there is a significant difference regarding the overdose rate in each administration route (P = 0.005). IV bolus is more likely associated with
supratherapeutic dose compared to IM injection (P = 0.009) and SC injection (P = 0.005). There is no significant difference in overdose rate between IM
injection and SC injection (P = 1.000)
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consistent with a recent study from China [16]. TCM injections
have relatively complex formulations and may cause anaphylaxis
[5, 16], thus they should be avoided if possible. Although non-
steroidal anti-inflammatory drugs (NSAIDs) are important triggers
for DIA in adults [1, 6], our analysis did not observe any NSAID-
induced anaphylaxis, which is consistent with a previous study
reporting thatNSAIDswere infrequent causes of pediatric anaphy-
laxis [19].
Target organ involvement and clinical manifestations
during anaphylaxis reactions of DIA children
The two most frequent clinical features of DIA in our study
were overall cardiovascular and respiratory manifestations,
followed by mucocutaneous symptoms. Although mucocuta-
neous symptoms are generally considered as a typical sign of
allergy, our study implies that absence of such symptoms
might not be sufficient to exclude the diagnosis of anaphylax-
is. Among three age groups, we observed significant differ-
ences for some symptoms (neurological systems, cyanosis,
hypotension, and nausea) and anaphylaxis severity, which is
in line with previous studies that observed age-related patterns
in the clinical presentation of pediatric anaphylaxis [10, 24].
Considering age differences regarding DIA, symptoms could
facilitate early recognition and prompt treatment of this poten-
tially life-threatening condition.
The present study found that 36% of DIA children had
gastrointestinal manifestations, with emesis and abdominal
cramping as the most common symptoms. This is consistent
with a previous study [29], suggesting that gastrointestinal
symptoms should be assessed when considering DIA, and
abdominal cramping should especially arouse concern in 0–
5-year-old children because they may not accurately express
this discomfort.
Epinephrine administration and pediatric DIA
Similar to our study, the underuse of epinephrine has also been
described by previous studies [3, 30]. As the first-line treat-
ment in anaphylaxis, epinephrine is recommended by primary
guidelines [21, 26, 28]. The low frequency of epinephrine
utilization and not using it as the initial therapy in our study
could be related to the failure to recognize anaphylaxis initial-
ly or the perceived severity of adverse reactions associated
with the use of epinephrine. Clinicians should use epinephrine
as a first-line therapy as soon as they make a diagnosis of
anaphylaxis since delayed epinephrine administration is asso-
ciated with a risk of hospitalization and poor outcomes [2, 8].
Our study showed a higher percentage of IV injection (bo-
lus and continuous infusion) but lower intramuscular use.
More than two thirds of the administration route was by IV
bolus. Studies have found that epinephrine administered by
the IM route achieves peak concentrations faster than that
Table 4 The information of 20
epinephrine-supratherapeutic
dosing pediatric patients
Number Age
(years)
Epinephrine as an initial
treatment*
Route of
epinephrine
Dose of epinephrine
(mg)
1 2.5 Y IV bolus 0.50
2 4.0 Y IV bolus 0.50
3 4.2 Y IV bolus 3.00
4 9.0 N IV bolus 0.50
5 10.0 N IV bolus 0.30
6 10.2 Y IV bolus 1.00
7 13.0 Y IV bolus 0.50
8 14.2 N IV bolus 0.50
9 14.9 N IV bolus 0.50
10 15.1 N IV bolus 1.00
11 17.9 Y IV bolus 0.20
12 4.0 Y IM 0.20
13 4.7 Y IM 0.33
14 8.5 N IM 1.00
15 17.2 Y IM 1.00
16 2.0 Y SC 0.30
17 3.7 Y SC 0.50
18 3.8 Y SC 0.30
19 4.0 Y SC 0.30
20 5.8 Y SC 0.40
*Y, epinephrine as an initial treatment; N, epinephrine not as an initial treatment
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given by subcutaneous injection, and IM is also safer than the
IV bolus injection [4, 27]. IV continuous infusion of epineph-
rine should be preferred when anaphylaxis patients do not
respond to repeated IM injections [21]. The underuse of the
IM administration may be because that physicians do not rec-
ognize that IM is the optimal route in anaphylaxis treatment,
thus further education is needed.
This study showed that the overdosing frequency of epi-
nephrine is quite high, especially with the IV bolus route, which
was consistent with a recent study [4]. Among the 20
supratherapeutic dosing patients, 10 were 0–5 years old, and
13 patients were administered epinephrine exceeding the rec-
ommended maximum dose, especially with the IV bolus route.
This high frequency of supratherapeutic dosing may be due to
(1) the overuse of IV bolus injection, (2) the perceived severity
of the anaphylaxis signs and symptoms, (3) physicians not
knowing the recommended maximum dose of epinephrine in
treating anaphylaxis, especially for the 0–5 year age group, and
(4) confusion about the recommended dose treating anaphylax-
is with the dose treating cardiac arrests. The fact that only one
epinephrine formulation (1:1000, 1 mg/ml) is available in
China may also contribute to the high frequency of overdosing.
IV bolus administration of epinephrine should be avoided
whenever possible due to the risk of cardiac arrhythmias and
potential for inappropriate dosing [4]. The epinephrine dosing
by IV bolus injection in anaphylaxis is also significantly lower
than the dose recommended for cardiac arrest (1 mg of 1:10,000)
IV bolus [7]. Caution should be exercised when treating the 0–5-
year-old age group especially with an IV bolus as overdosing
tends to occur more frequently based on our analysis.
Other common treatments in pediatric patients with DIA
Our study observed a higher frequency of corticosteroids use
compared to epinephrine use despite corticosteroids is recom-
mended only as second-line adjunctive therapy [21, 26, 28].
Additionally, when used as the only initial monotherapy, cor-
ticosteroid use was approximately two times higher than epi-
nephrine. This discrepancy between practice and guidelines
[21, 26, 28] may be because physicians fail to recognize that
epinephrine should be the cornerstone and first-line therapy in
anaphylaxis.
Although wheezing and dyspnea symptoms each accounted
for about 20% of anaphylaxis in children, only 4% of them
were administered inhaled short-acting beta-2 agonists. This
suggests that β2-agonist inhalation treatment should be en-
hanced in anaphylaxis management in order to quickly alleviate
lower respiratory tract symptoms. Furthermore, although a pre-
vious study showed that the combination of systemic H1- and
H2-antihistamines are more beneficial than H1-antihistamine
monotherapy in relieving some cutaneous symptoms in those
experiencing acute allergic reactions [18], only 1 of our patients
received H2-antihistamines.
Limitations
The study has several limitations: (1) the analysis was based
on self-reported cases by health care professionals from the
BPD, which may include incomplete data; (2) we may not
include all DIA pediatric patients: cases missed if clinicians
did not report using the terms related to allergy or anaphylaxis
or hypersensitivity; and (3) the sample size was small. The
method we have taken should be robust against a range of
potential biases: rigorous inclusion/exclusion criteria were uti-
lized and all potential anaphylaxis cases were adjudicated by
trained physician/allergists; and only patients with complete
data record were included in the analysis.
The present study showed there were differences in clinical
symptoms and severities of DIA among 0–5, 6–12, and 13–
17-year-old patients. For DIA in pediatric patients in the
Beijing area, we found that the three common triggers were
antibiotics, TCM injections, and biologics. Epinephrine was
underused compared to corticosteroids in the treatment of
anaphylaxis. IV bolus of epinephrine was overused and was
associated with supratherapeutic dosing.
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